Correlation of Serum TNF -ALPHA & Interferon - Gamma Level with H & Y Scale of Parkinson's Disease
DOI:
https://doi.org/10.52783/jns.v14.2320Keywords:
Serum TNF-α, Interferon- γ level, Parkinson disease, Disease severityAbstract
Aim: The aim of the present study was to examine the relationship of Serum TNF-α and Interferon- γ level in Parkinson disease and Disease severity.
Methods: This research was carried out among patients presented to Department of General Medicine, Vinayaka Mission’s Medical College, Karaikal over an 18-month period. A total of 44 individuals were part of the study.
Results: Majority participants fall in the age group of 71-80. The age distribution range was 57-88, while the mean age of the participants was 73.16±8.80 years. The male: female ratio is approximately 2:1 in this study. Majority of participants belonged to moderate disability (65.9%) and minimum number of cases were in server or advanced disability (11.4%). Majority of participants belonged to grade 3(38.6%), which least number of participants belonged to grade 5(6.8%). 34 cases had hypertension, which is 77.3 % of the cases. 31 cases had DM-T2 which is 70.4 % of the cases.
Conclusion: We concluded in our study that gene expression of INF-γ and TNF-α were higher in patient with Severe form of PD. But the P-Value of these inflammatory markers were not statistically significant. A multi-centric study cross- sectional study should be done for further study.
Downloads
Metrics
References
Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta‐analysis. Movement disorders. 2014 Nov;29(13):1583-90.
Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):795-808.
Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022 Nov;22(11):657-673.
Harms AS, Ferreira SA, Romero-Ramos M. Periphery and brain, innate and adaptive immunity in Parkinson's disease. Acta Neuropathol. 2021 Apr;141(4):527-545.
Karikari AA, McFleder RL, Ribechini E, Blum R, Bruttel V, Knorr S, Gehmeyr M, Volkmann J, Brotchie JM, Ahsan F, Haack B, Monoranu CM, Keber U, Yeghiazaryan R, Pagenstecher A, Heckel T, Bischler T, Wischhusen J, Koprich JB, Lutz MB, Ip CW. Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson's disease mice. Brain Behav Immun. 2022 Mar;101:194-210.
Lindestam Arlehamn CS, Dhanwani R, Pham J, Kuan R, Frazier A, Rezende Dutra J, Phillips E, Mallal S, Roederer M, Marder KS, Amara AW, Standaert DG, Goldman JG, Litvan I, Peters B, Sulzer D, Sette A. α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease. Nat Commun. 2020 Apr 20;11(1):1875.
Kustrimovic N, Comi C, Magistrelli L, Rasini E, Legnaro M, Bombelli R, Aleksic I, Blandini F, Minafra B, Riboldazzi G, Sturchio A, Mauri M, Bono G, Marino F, Cosentino M. Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. J Neuroinflammation. 2018 Jul 12;15(1):205.
Wang P, Yao L, Luo M, Zhou W, Jin X, Xu Z, Yan S, Li Y, Xu C, Cheng R, Huang Y, Lin X, Ma K, Cao H, Liu H, Xue G, Han F, Nie H, Jiang Q. Single-cell transcriptome and TCR profiling reveal activated and expanded T cell populations in Parkinson's disease. Cell Discov. 2021 Jul 20;7(1):52.
Gate D, Tapp E, Leventhal O, Shahid M, Nonninger TJ, Yang AC, Strempfl K, Unger MS, Fehlmann T, Oh H, Channappa D, Henderson VW, Keller A, Aigner L, Galasko DR, Davis MM, Poston KL, Wyss-Coray T. CD4+ T cells contribute to neurodegeneration in Lewy body dementia. Science. 2021 Nov 12;374(6569):868-874.
Subbarayan MS, Joly-Amado A, Bickford PC, Nash KR. CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases. Pharmacol Ther. 2022 Mar;231:107989.
Epidemiology of Parkinson's disease, de Lau LM, Breteler MM, Lancet Neurol. 2006;5(6):525.
Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
Rong S, Xu G, Liu B, Sun Y, Snetselaar LG, Wallace RB, Li B, Liao J, Bao W. Trends in mortality from Parkinson disease in the United States, 1999–2019. Neurology. 2021 Nov 16;97(20):e1986-93.
El-Kattan MM, Rashed LA, Shazly SR, Ismail RS. Relation of serum level of tumor necrosis factor-alpha to cognitive functions in patients with Parkinson’s disease. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2022 Feb 19;58(1):25.
Kouchaki E, Kakhaki RD, Tamtaji OR, Dadgostar E, Behnam M, Nikoueinejad H, Akbari H. Increased serum levels of TNF-α and decreased serum levels of IL-27 in patients with Parkinson disease and their correlation with disease severity. Clinical neurology and neurosurgery. 2018 Mar 1;166:76-9.
Shen L, Ji HF. Low uric acid levels in patients with Parkinson's disease: evidence from meta-analysis. BMJ open. 2013 Nov 1;3(11):e003620.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
